The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy.
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - Immunomedics; Janssen; Sanofi; Sanofi
Research Funding - Agensys (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Christos Kyriakopoulos
Consulting or Advisory Role - Exelixis
Speakers' Bureau - The France Foundation
Research Funding - Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Susan F. Slovin
Consulting or Advisory Role - Bayer; Clovis Oncology; Pfizer
Speakers' Bureau - OncLive; PER; Prime Oncology; Society for Immunotherapy of Cancer
Research Funding - AstraZeneca
 
Jens C. Eickhoff
Consulting or Advisory Role - Five Prime Therapeutics
Research Funding - Sanofi Pasteur (Inst)
 
Scott Dehm
Consulting or Advisory Role - Celgene
Research Funding - Janssen Research & Development (Inst); Medivation/Astellas (Inst)
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Novartis; Pfizer; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi